QCLS — Q/C Technologies, Inc.
NASDAQ · Technology · Computer Hardware
$2.09
+$0.00 (+0.00%)
Q/C Technologies, Inc. (QCLS) is a computer hardware company listed on NASDAQ. It is led by Joshua N. Silverman, based in 1185 Avenue of the Americas, New York, NY, United States, 10036, with about 2 employees. Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Net income was -$2.8M. QCLS currently screens at market cap $30.7M.
Use this QCLS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QCLS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QCLS SEC filings page. Lician reads the product cache first so this HTML stays unique to Q/C Technologies, Inc. even when a live quote feed is slow.
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
QCLS Key Statistics
Market Cap
$30.71M
Volume
47,082
Previous Close
$2.41
Day Range
$2.40 – $2.50
P/B Ratio
1.55
EPS
-$11.15
Revenue
$0.00
Net Income
-$23.36M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
QCLS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$23.36M | -$4.00M | -$15.20M | -$29.89M |
| EPS (Diluted) | -$11.15 | -$5.33 | -$11.74 | $0.00 |
Total Assets
$21.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$173.15K
Operating Cash Flow
-$8.98M
Free Cash Flow
$0.00
Q/C Technologies, Inc. Company Information
- Executive Chairman of the Board
- Joshua N. Silverman
- Headquarters
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Website
- www.qctechnologies.com
- Phone
- 856 848 8698
- IPO / Founded
- 2014-01-23
- Sector
- Technology
- Industry
- Computer Hardware